Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
UPLD....................DZSI...............................MULN,,,,,,,,,,,,,,,,,,https://stockcharts.com/h-sc/ui?s=UPLD&p=D&yr=0&mn=3&dy=0&id=p11960084343
https://stockcharts.com/h-sc/ui?s=DZSI&p=D&yr=0&mn=3&dy=0&id=p11960084343
https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=3&dy=0&id=p11960084343
GROY......AKBA......MULN..................................
$MULN
— TGS Trades (@TGS_Trades) May 4, 2024
05.04.24 Saturday update for #MULN:
- Up 32% net over past 5 trading days. $3.16 to $4.16.
- Approved for $45K HVIP rebate in CA for Mullen 3 trucks, plus $7.5K federal rebate.
- Adds large commercial electric dealer to network (Pritchard Electric)
- Short interest… pic.twitter.com/i0XjVBXMIu
$NCL News: Northann Corp.'s Blue11-Ocean Plastic Flooring and Wall Panels Product Wins Multiple Prestigious Awards in 2024
ELK GROVE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Northann Corp. (NYSE American: NCL), a leader in innovative sustainable solutions, today announced that its Blue11-Ocean Plastic Flooring and Wall Panels Product has been recognized this year with industry awards for outstanding design, commitment to sustainability, and impeccable craftsmanship.
These awards include:
American Good Design Award 2024
French Design Award 2024
IDA Design Awards 2024
New York Product Design Awards
Green Product Award
Best Surfaces in TISE 2024
"We are truly honored to receive these prestigious awards, which underscore our commitment to creating products that are not only visually captivating but also environmentally conscious," remarked Northann Corp. CEO Lin Li. "This recognition fuels our passion to continue delivering innovative and sustainable solutions that resonate with our customers and contribute positively to the environment.
“Northann Corp.'s Blue11-Ocean Plastic Flooring and Wall Panels Product stands as a shining example of our company's enduring pursuit of excellence and sustainability.”
To learn more about this award-winning product and Northann Corp.'s comprehensive range of sustainable solutions, please visit www.northann.com and www.benchwick.com.
About Northann Corp.
Northann specializes in 3D-printed flooring solutions under its flagship brand, "Benchwick." The Company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. Northann offers its 3D printing ecosystem as an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, primarily through its sales network in North America and Europe. The Company aims to redefine the essence of modern flooring and wall panels by offering stylish, durable, and ecologically conscious solutions.
For more information about Northann, please visit http://www.northann.com.
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For investor and media inquiries, please contact:
Investor Relations
Northann Corp.
Email: ir@northann.com
Phone: +1 (916) 573-3803
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor New York, NY, 10036
Office: (646) 893-5835 x2
Email: info@skylineccg.com
BLNK.....CHPT......EVGO.....MULN.......
$MULN
— TGS Trades (@TGS_Trades) May 4, 2024
05.04.24 Saturday update for #MULN:
- Up 32% net over past 5 trading days. $3.16 to $4.16.
- Approved for $45K HVIP rebate in CA for Mullen 3 trucks, plus $7.5K federal rebate.
- Adds large commercial electric dealer to network (Pritchard Electric)
- Short interest… pic.twitter.com/i0XjVBXMIu
NO RESISTANCE; for PlantX Lifestyle today;
3rd Resistance Point 0.0250
2nd Resistance Point 0.0250
1st Resistance Point 0.0250
Last Price 0.0250
1st Support Level 0.0250
2nd Support Level 0.0250
3rd Support Level 0.0250
Monday next week earnings report out
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174356987
$PDGO - In this regard, the related entity has executed several new Letters of Intent for additional acquisitions in furtherance of the Company's strategy. The related entity is presently engaged in the diligence necessary to bring the Letters of Intent to contract and closing.
https://www.otcmarkets.com/stock/pdgo/news/Paradigm-Oil--Gas-Inc-PDGO-Expands-Market-Presence-with-Proposed-Strategic-Oil-and-Gas-Acquisitions?id=439005
$WRIT - WRIT Media is thrilled to announce the launch of its innovative NFT Minting Engine, a state-of-the-art blockchain-powered solution designed to revolutionize how digital assets and awards are created, distributed, and valued in live esports competitions and gaming tournaments.
https://www.otcmarkets.com/stock/WRIT/news/New-Era-in-Blockchain-Gaming-Writ-Media-Group-Inc-Announces-Launch-of-Revolutionary-NFT-Minting-Engine-to-Transform-Espo?id=437361
$RENB News: Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics
LOS ANGELES and AMSTERDAM, April 30, 2024 (GLOBE NEWSWIRE) -- RenovaroCube, wholly owned subsidiary of Renovaro, Inc. (Nasdaq: RENB), a company at the forefront of AI-driven healthcare innovation, proudly unveils Flamingo, a potentially groundbreaking multi-cancer detection model contributing to its mission to transform early cancer diagnostics. Leveraging ultra-low pass whole genome sequencing (ULP-WGS) of cell-free DNA (cfDNA), Flamingo represents a promising leap forward in the fight against cancer.
Traditional cancer detection methods often fall short in identifying cancers at an early stage when treatment is the most effective. However, Flamingo has the potential to overcome these limitations by harnessing the power of AI to analyze minute amounts of cfDNA data that is highly accurate.
"At RenovaroCube, we believe in pushing the boundaries of possibility," states Daan Vessies, senior scientist at RenovaroCube. "Flamingo undescores our commitment to change cancer diagnostics in a transformative way, ultimately offering clinicians a powerful tool to detect cancer across diverse omic layers."
The Company believes that no single model or molecular modality will reach the requisite sensitivity and specificity throughout the entire patient journey for personalized, precision medicine, from early detection, to predicting the effectiveness of various treatment options, to monitoring the response to therapy within days of starting it, to detecting recurrence at the earliest possible moment. Therefore, our AI/machine learning platform, The Cube, integrates multi-omic data, offering a uniquely comprehensive approach to cancer detection by leveraging a library of trained models for multiple omic layers. One such model Flamingo focuses on is the detection of cancer from ultra-low pass whole genome sequencing (ULP-WGS) cfDNA data using fragmentomics.
Flamingo's development marks a significant milestone in the quest for early cancer detection with RenovaroCube’s engine. By utilizing as few as only 200,000 cell-free DNA fragments per sample, integrating fragment lengths, sequence motifs and employing a meticulously designed neural network, Flamingo achieves remarkable performance in distinguishing cancer from healthy samples.
By augmenting The Cube's arsenal of models operating across various omic layers, Flamingo contributes to the development of non-invasive diagnostics to detect cancer early, enabling timely interventions and improving patient outcomes.
"Adding Flamingo to our Cube will accelerate our efforts to realize a paradigm shift in cancer detection," affirms Frank van Asch, CTO, RenovaroCube. "With its introduction, we are one step closer to realizing our vision of a world where cancer is detected and treated swiftly, saving countless lives in the process."
RenovaroCube invites interested doctors and scientists from international research institutions, clinical cancer centers and all stakeholders to join in the early research use application of our AI/machine learning platform to advance cancer diagnostics and pave the way for a healthier future.
About Renovaro:
Please see a recent interview with Avram Miller, Member of, and Advisor to, the Board of Directors, former co-founder of Intel Capital and SVP of Business Development for Intel:
https://techbullion.com/avram-miller-talks-about-renovaro-and-its-impact-in-diagnosing-cancers-and-infectious-diseases-with-ai
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro includes RenovaroBio, with its advanced cell-gene immunotherapy company, and RenovaroCube. RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
Upon the closing of the previously announced acquisition of Cyclomics (winner of the Health Holland Venture Challenge), RenovaroCube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. This will transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.
https://www.renovarogroup.com
https://www.renovarobio.com
https://www.renovarocube.com
About Cyclomics:
Cyclomics is a Dutch company founded in 2018, winner of the Health Holland Venture Challenge (startup of the year) by scientists of the UMC Utrecht. Its ambition is to transform cancer care by enabling faster and more reliable diagnoses, particularly in the context of cancer recurrence thanks to its proprietary circulating tumor DNA (ctDNA) detection technology.
https://www.cyclomics.com/
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
https://www.globenewswire.com/newsroom/ti?nf=OTEwODQ5OCM2MjI2Njk4IzIxMjA2Nzk=
https://ml.globenewswire.com/media/OThkZGJkYzMtMDEzYi00YTcxLThhZWEtZDdmMDQ2ZDA4NzdlLTExMzIyNTA=/tiny/Renovaro-Inc.png
Source: Renovaro Inc
People don't understand how good this News is...
$AGBA
$AGBA Conor McGregor is now an owner of BKFC!
Triller is the majority owner of BKFC
$PDGO - The asset was acquired by a PDGO-related company with full integration into PDGO to be completed upon the asset being audited. This strategic move further solidifies PDGO's commitment to growth and innovation in the energy sector.
https://www.otcmarkets.com/stock/PDGO/news/PDGO-Announces-Acquisition?id=436678
GROY..............AKBA..................MULN............................https://www.mullenusa.com/battery
$AGBA 🛫🛫MERGER NEWS EXPLODING! #SHORTSQUEEZE
GREAT YOU TUBE VIDEO!
$PNPNF - Inflation Reduction Act
Power Nickel Inc. stands ready to address the critical nickel shortage, essential for EV batteries, amidst growing scarcities due to the Inflation Reduction Act's stringent sourcing requirements.
https://reports.stocknewstrends.com/facing-a-20x-surge-in-demand-this-hidden-gem-could-be-sitting-on-a-potential-billion-dollar-nickel-deposit?utm_source=corporateads&utm_medium=affiliate&utm_campaign=pnpnf_us&utm_id=pnpnf_us
AKBA...................MULN................................https://stockcharts.com/h-sc/ui?s=AKBA&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=2&dy=12&id=p84071410134
GROY...........................https://stockcharts.com/h-sc/ui?s=GROY&p=D&yr=0&mn=2&dy=12&id=p84071410134
Sorry, the previous post "ES Mining" has a broken link, I attach one that works;
https://crweworld.com/article/news-provided-by-globenewswire/3364861/romania-government-announces-strategy-to-align-mining-legislation-to-the-eu-s-critical-raw-materials-act
$GTVH News April 25, 2024
Golden Triangle Ventures Announces Four-Pillar Business Model for Lavish Entertainment
https://finance.yahoo.com/news/golden-triangle-ventures-announces-four-120000166.html
ES Mining Progress, Romania Government to Align Mining Legislation to the EU 's Critical Raw Materials Act
https://crweworld.com/article/news-provided-b...erials-act
BOF......CZOO......MULN......XXII.......https://stockcharts.com/h-sc/ui?s=BOF&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=CZOO&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=XXII&p=D&yr=0&mn=2&dy=12&id=p84071410134
$RONN Agrees to Work with H2H to Integrate Their Patented Products into Ronn Inc. Global Projects
SCOTTSDALE, AZ / ACCESSWIRE / April 16, 2024 / Ronn, Inc (OTC PINK:RONN). Ronn Ford, the companies CEO, announced today that RONN Inc. and H2H, along with its various partners globally, will sign a LOI to integrate and commercialize H2H's many hydrogen proprietary products, which include leading-edge proprietary hydrogen storage and hydrogen a/c systems. Additionally, as they become available, the agreement details will be updated.
Mr. Ford added that our friends at H2H already have agreements with groups in India with whom we are presently developing commercial relationships and potential Joint Ventures. A partnership with H2H would potentially open doors for many of the groups they are already in relationships. We are very excited to integrate their patented hydrogen storage and hydrogen a/c systems. See more details about our friends at their latest link below.
https://www.lokmattimes.com/business/bses-game-changing-partnership-mercury-ev-tech-ventures-into-hydrogen-storage-manufacturing/
For media inquiries, please contact:
For more information, go to www.ronnmotorgroup.com or contact John Morgan at jmorgan@ronnmotorgroup.com
About RONN, Inc.
RONN, Inc. is a forward-thinking company dedicated to making a positive impact on the environmental credit market. With a commitment to innovation and sustainability in the commercialization of Hydrogen in both mobile and stationary sectors, RONN, Inc. strives to create value for both its shareholders and the planet.
https://finance.yahoo.com/news/ronn-inc-agrees-h2h-integrate-121500419.html
$AGBA Seeking Alpha Article April 22, 2024
AGBA Group: Triller Merger Creates Significant Speculative Upside If TikTok Gets Banned In The U.S.
https://seekingalpha.com/article/4685179-agba-group-triller-merger-creates-significant-speculative-upside-if-tiktok-gets-banned-in-the-us
SNDL......TLRY.......MULN.......CZOO..................https://stockcharts.com/h-sc/ui?s=CZOO&p=D&yr=0&mn=3&dy=0&id=p11960084343
.https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=3&dy=0&id=p11960084343
https://stockcharts.com/h-sc/ui?s=SNDL&p=D&yr=0&mn=3&dy=0&id=p11960084343
https://stockcharts.com/h-sc/ui?s=TLRY&p=D&yr=0&mn=3&dy=0&id=p11960084343
$MNTS and $ASTI Partnership: Momentus and Ascent Solar Technologies Partner to Bring Leading-Edge Solar Arrays to Market
Innovative solar arrays to address burgeoning demand
SAN JOSE, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Momentus Inc. (NASDAQ: MNTS) ("Momentus") and Ascent Solar Technologies, (Nasdaq: ASTI) (“Ascent”) today announced a new partnership to jointly market leading-edge solar arrays utilizing the low-cost Tape Spring Solar Array (TASSA) being developed by Momentus and the high performance of Ascent’s flexible, lightweight photovoltaic modules.
The rapid growth in the production and deployment of thousands of satellites in space has led to the burgeoning need for low-cost, reliable and high performing solar arrays. Momentus and Ascent are excited to partner to market a leading-edge solar array designed to provide key advantages to customers such as lower costs, resiliency with less degradation in the harsh environment in space, flexibility, and the ability to efficiently generate large amounts of power.
Building off the successes of the pathfinder demonstration of TASSA that was launched to Low-Earth Orbit on the Vigoride-6 mission one year ago and tested in space for several months, Momentus plans to add a high-power photovoltaic array as a differentiated feature of the next iteration of the TASSA product under development. Last year’s pathfinder TASSA demonstration validated solar blankets from Ascent, as a mass efficient and robust power generation solution. Momentus plans to incorporate in TASSA new higher efficiency solar blankets from Ascent composed of space industry optimized Titan Modules, achieving even lower cost per kW of power.
TASSA will continue to utilize Vigoride hardware with spaceflight heritage to provide customers an entire array subsystem, complete with solar array rotation actuators and controllers. This approach is oriented at streamlining mission schedules and minimizing clean room bottlenecks during spacecraft assembly integration and testing. TASSA is designed for responsive launch as well as more efficient flatpack configurations which allow for more satellites to fit within launch vehicle payload fairings.
“TASSA is designed to generate extensive power at very low cost while minimizing mass and volume,” said Rob Schwarz, Momentus CTO. “TASSA is intended to allow Smallsats to generate kilowatts of power on orbit without breaking their mass, thermal, or cost budgets. This design optimization also facilitates improved satellite packing efficiencies and allows constellations to be fielded quicker and cheaper.”
TASSA is also retractable and re-deployable providing a means for the minimization of cross-sectional area and array exposure if notified of potential conjunction or other orbital hazards such as space weather. This could enable TASSA to facilitate longer mission durations and increased assurance of spacecraft operations on orbit.
“Ascent’s flexible, lightweight photovoltaic modules are ideal for the space environment,” said Paul Warley, CEO of Ascent Solar Technologies. “Our CIGS products are resilient to radiation and other drivers of degradation while operating in orbits between the Earth and the Moon. For those designing space missions, this equates to more end-of-life power with an order of magnitude less mass. We’re excited to be the baseline power generation solution for TASSA, and look forward to continuing to collaborate with the Momentus team to provide long-lived and sustainable solutions for proliferated space architectures.”
ABOUT MOMENTUS
Momentus is a U.S. commercial space company that offers satellite buses and technologies, as well as space services including transportation, hosted payloads, and other in-orbit services.
ABOUT ASCENT SOLAR TECHNOLOGIES, INC.
Backed by 40 years of R&D, 15 years of manufacturing experience, numerous awards, and a comprehensive IP and patent portfolio, Ascent Solar Technologies, Inc. is a leading provider of innovative, high-performance, flexible thin-film solar panels for use in environments where mass, performance, reliability, and resilience matter. Ascent’s photovoltaic (PV) modules have been deployed on space missions, multiple airborne vehicles, agrivoltaic installations, in industrial/commercial construction as well as an extensive range of consumer goods, revolutionizing the use cases and environments for solar power. Ascent Solar’s research and development center and 5-MW nameplate production facility is in Thornton, Colorado. To learn more, visit https://www.ascentsolar.com or follow the Company on LinkedIn and X (formerly Twitter).
Forward-Looking Statements
This press release contains certain statements which may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding Momentus or its management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, and are not guarantees of future performance. The words “may,” “will,” “anticipate,” “believe,” “expect,” “continue,” “could,” “estimate,” “future,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “aim,” “strive,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions.
Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Momentus’ control. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: the ability of the Company to generate revenue and raise capital in order to continue as a going concern; the ability of the Company to obtain licenses and government approvals for its missions, which are essential to its operations; the ability of the Company to effectively market and sell satellite transport services and planned in-orbit services; the ability of the Company to protect its intellectual property and trade secrets; the development of markets for satellite transport and in-orbit services; the ability of the Company to develop, test and validate its technology, including its water plasma propulsion technology; delays or impediments that the Company may face in the development, manufacture and deployment of next generation satellite transport systems; the ability of the Company to convert backlog or inbound inquiries into revenue; changes in applicable laws or regulations and extensive and evolving government regulations that impact operations and business, including export control license requirements; the ability to attract or maintain a qualified workforce with the required security clearances and requisite skills; product service or product or launch failures or delays that could lead customers to use competitors’ services; investigations, claims, disputes, enforcement actions, litigation and/or other regulatory or legal proceedings; the Company’s ability to comply with the terms of its National Security Agreement and any related compliance measures instituted by the director who was approved by the CFIUS Monitoring Agencies; the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and/or other risks and uncertainties. These are only some of the factors that may affect the forward-looking statements contained in this press release. For a discussion identifying additional important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, see the company’s filings with the U.S. Securities and Exchange Commission including, but not limited to, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The Company’s filings may be accessed through the Investor Relations page of its website, investors.momentus.space, or through the website maintained by the SEC at www.sec.gov. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
MEDIA CONTACT
Spencer Herrmann
FischTank PR
ascent@fischtankpr.com
INVESTOR RELATIONS CONTACT
ir@ascentsolar.com
https://www.globenewswire.com/newsroom/ti?nf=OTA5MDY1OSM2MjA0NDU2IzUwMDExNDU4Mw==
https://ml.globenewswire.com/media/NWI4MGQxZTUtZDM5My00M2QwLWEzNjAtYjFiM2Q2NTVkYmUzLTUwMDExNDU4Mw==/tiny/Ascent-Solar-Technologies-Inc-.png
Source: Ascent Solar Technologies, Inc.
AKBA................MULN..............................https://stockcharts.com/h-sc/ui?s=AKBA&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=2&dy=12&id=p84071410134
$IVDN (16 million float) News on Rising Sales of Superior Insulation Product: Innovative Designs Vendor Growth
PITTSBURGH, PA, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovative Designs, Inc. (OTCQB: IVDN) continues to gain market share through its growing vendor base. Since the beginning of this fiscal year (November 1, 2023), Innovative Designs has added over 30 new accounts that have purchased its Insultex House Wrap®. This has resulted in a comp sales increase of 318% as compared to the same time period last year (November 2022 – April 2023). With 7 months remaining in FY2024, sales for the first 5 months are approaching 88% of last year's total.
Randy Kimbler, a National Distributor of Insultex, commented, “The introduction of Insultex® House Wrap to several major building supply companies has been very well-received. The product is being placed in the retail locations of these organizations, as well as many local building supply companies. The R-6 insulation value provided by this very thin product has proven to be an affordable solution for builders facing economic challenges in states where energy codes require R-5 Continuous insulation for new construction.”
About Innovative Designs, Inc.
Innovative Designs, Inc. manufactures the Insultex® House Wrap and Arctic Armor® Line, under the "i.d.i.gear" label featuring INSULTEX®. Patented INSULTEX® is the thinnest, lightest and warmest insulator in the market today. For more information, please visit http://www.idigear.com or http://www.insultexhousewrap.com.
Disclaimer
Certain statements in this press release constitute "forward-looking" statements as defined by federal law. Such statements are based on assumptions, but there is no assurance that actual outcomes will not be materially different as those implied. Any such statements are made in reliance on the "Safe Harbor" protections provided under the Private Securities Reform Act of 1995 and are subject to various factors, including the risks and matters discussed in the Company's SEC filings available at http://www.sec.gov.
CONTACT:
Innovative Designs, Inc.
Joseph Riccelli, CEO
412-799-0350
joer@idigear.com
Website: http://www.insultexhousewrap.com
Link: https://finance.yahoo.com/news/innovative-designs-vendor-growth-173800119.html
ALCOHOL! New Video PlantX CEO Sean Dollinger Spills Secrets
in Interview with Michael Nauss!
$NRXP News: NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections
New data demonstrates no impact of NRX-101 on gut or vaginal flora – considered primary causes of pseudomembranous colitis due to C difficile and vaginal yeast infections
NRX-101 previously demonstrated potent activity against resistant urinary pathogens and has been shown to be fully excreted, unmetabolized, in the urine
NRX-101 has received FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation in Complicated Urinary Tract Infection (cUTI) and Pyelonephritis
RADNOR, Pa., April 17, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", "NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced new data that demonstrate that in a rodent model NRX-101 shows no measurable damage to either intestinal or vaginal flora, compared to the significant negative effect caused by drugs such as ciprofloxacin. Antibiotics commonly used to treat complicated urinary tract infections (cUTI) are associated with pseudomembranous colitis caused by Clostridium difficile (C diff) and vaginal yeast infections, primarily owing to their impact on normal flora.
C. diff causes an intractable diarrhea in approximately 500,000 Americans each year and kills 1 in 11 Americans over age 65 who contract the infection. Costs of C. diff are estimated at $24,000 per patient and are significantly higher when C. diff occurs as part of a hospital admission. Whereas most antibiotics have substantial effect in the large bowel, the key component of NRX-101 (D-cycloserine) is entirely absorbed in the small intestine and excreted unmetabolized in the urine. If the nonclinical data reported today are replicated in patients, NRX-101 could represent the first antibiotic for cUTI and pyelonephritis that has essentially no risk of causing C. diff infection or vaginal yeast infection. There is an extensive literature surrounding the use of D-cycloserine to treat tuberculosis and cases of C. Diff are unknown.
D-cycloserine's effect as an antibiotic is based on its propensity to substitute for the amino acid alanine in the formation of the bacterial cell wall.
Dr. Michael Manyak, noted Professor of Urology and former Global Medical Director for Urology at Glaxo SmithKline stated "As a Urologist, I'm acutely aware of the importance of avoiding common side effects of current antibiotics. NRX-101's lack of impact on normal flora could potentially confer a distinct advantage for the product in for the treatment of cUTI and pyelonephritis. This profile could change the lives of the half million Americans each year who contract C. diff and save lives among the tens of thousands who die from antibiotic-induced C. diff infections. These potential advantages should make NRX-101 even more attractive to potential partners in this multi-billion-dollar market." Dr. Manyak serves as NRx's Medical Thought Leader for urology.
"While we have primarily focused on NRX-101 as a drug to treat CNS disease, these new and highly provocative findings suggest that NRX-101 could find a home as a first line treatment for cUTI and pyelonephritis, which afflicts more than 3 million Americans each year. Should the rodent model findings prove applicable to the people, the use of NRX-101 to treat cUTI without increasing the risk of C. diff infection could have multibillion dollar potential," said Stephen Willard, JD, Chief Executive Officer of NRx pharmaceuticals.
About D-Cycloserine in cUTI
The active antibiotic ingredient of NRX-101 is D-cycloserine (DCS) that was developed as an antibiotic in the 1950's and used worldwide for the treatment of tuberculosis. However, it fell out of favor with the development of trimethoprim/sulfa and various penicillins, cephalosporins, and tetracyclines, in part because of the CNS effects associated with DCS-induced blockade of the brain's NMDA receptor. In the course of its CNS research, NRx Pharmaceuticals has demonstrated that small doses of lurasidone counteract those CNS effects, potentially providing a new therapeutic life to DCS as an antibiotic. Over the ensuing decades, increased antibiotic resistance has rendered standard treatments for UTI ineffective in many cases and today 3 million Americans suffer from cUTI requiring increasingly toxic antibiotics, increasingly frequent intravenous therapy, and increased need for hospital admission. (Lodise TP, et. al. Open Forum Infectious Diseases https://doi.org/10.1093/ofid/ofac307)
Because DCS has the unique property of being highly concentrated, unmetabolized, in the urine with oral administration, the Company believes, and previous literature has suggested that DCS may effectively treat, and therefore help prevent, the need for intravenous and inpatient treatment of cUTI.
Moreover, because DCS is rapidly absorbed and excreted in the urine, NRX-101 has now been shown to have minimal tendency to disrupt the microbiome of the intestine and vagina and which can lead to secondary Clostridium difficile and/or yeast infections. C. diff associated colitis doubles hospital mortality and costs the American healthcare system up to $1.6 billion each year. (Drozd EM, et. al. Mortality, Hospital Costs, Payments, and Readmissions Associated With Clostridium difficile Infection DOI: 10.1097/IPC.0000000000000299) Additionally, DCS has no known association pulmonary fibrosis, a rare, lethal condition that has been associated with macrolide (tetracycline family) antibiotics.
NRX-101 has received FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations in Complicated Urinary Tract Infection and Pyelonephritis.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
https://c212.net/c/img/favicon.png?sn=CL90042&sd=2024-04-17 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-announces-new-data-on-nrx-101-demonstrating-no-damage-to-intestinal-and-vaginal-flora-in-validated-rodent-models-compared-to-standard-antibiotics-potential-implications-for-avoidance-of-c--302119157.html
SOURCE NRx Pharmaceuticals, Inc.
$NBIO - Mr. Carrick continued, "Phase I demonstrated an excellent safety profile at various doses. Phase II will be focused on clinical outcomes, and we are taking no shortcuts."
https://finance.yahoo.com/news/nascent-prepares-pivotal-phase-ii-120000620.html
$GSAC
🚨 $GSAC Next trip runner!
*1.2B float
*No dilution in recent months
*Added 1.2B shares to restricted 👀
- Catalysts:
*Talking about more announcements in the near future related to the acquisition
*upcoming annual report
*Expecting to establish a new research in south africa https://t.co/Z75TJ2uVDU pic.twitter.com/k8Yll9iocq
— NarutOTC (@NarutOTC_) April 11, 2024
To connect with the previous post - the start of PlantX, present status and thoughts
about the companies future growth.
$GTVH - This acquisition will transition ABI Create into a wholly owned subsidiary of Lavish Entertainment and bolster its position in the entertainment industry through ABI’s longstanding and exceptional reputation.
https://finance.yahoo.com/news/lavish-entertainment-inc-expands-presence-120000781.html
$AVRW New and Perfect Skincare Products. #OTCQB subisdiary@Seratopical
Solutions "Harmony Toner" Available on the Seratopical Website! Great video below with Facial Plastic Surgeon Dr. Michael Persky https://seralabshealth.com/products/ $JNJ $CVS $AMZN
$VVPR - VivoPower International PLC is pleased to confirm that its subsidiary Tembo e-LV B.V. has now met all of the milestones required to obtain the investment into Tembo, at a pre-money valuation of US$120M. The initial tranche has been received.
https://finance.yahoo.com/news/vivopower-secures-full-us-10m-111500807.html
$AGBA - The challenges faced in 2023 prompted successful changes to AGBA's business model, resulting in increased focus and efficiency. The implementation of significant cost-cutting measures is expected to reduce normalized operating expenses to a level for strong growth and profitability.
https://www.marketwatch.com/press-release/agba-group-is-positioned-for-hong-kong-s-rebounding-macro-environment-with-business-refinements-and-growth-strategies-f566e8f4
New directors 400 million accumulation
undervalued overlooked until its not
$GSAC #newdirectors #Update pic.twitter.com/NyEYyzVMdL
— Johnny President (@zarproductions1) February 27, 2024
STRONG BUY barchart.com Technical Opinion rating is a 96% Buy and ranks in the Top 1% of all short term signal directions. Long term indicators fully support a continuation of the trend. barchart.com PlantX will finally bounce back!
OTC: $TREIF CSE: $TRUE -- THE WORLD’S MOST INTELLIGENT, PERSONALIZED HEALTHCARE AI ENGINE https://treatment.com/investors/
$NXGB - Total years sales to be in the region of $1.3-$1.6m from the Mad House brand.
https://finance.yahoo.com/news/nxgen-brands-inc-releases-bullish-123000349.html
$GVH -Experience Effortless E-commerce Shipping: Globavend Holdings Limited (NASDAQ:GVH) Tailored Solutions from Hong Kong to Your Doorstep in Australia & New Zealand!
Click here: https://axecapitalusa.com/gvh/
Welcome to the future of logistics with Globavend Holdings Limited (NASDAQ:GVH), where innovation meets opportunity in the bustling e-commerce landscape of Asia-Pacific. As pioneers in direct injection from Hong Kong & Southern China to Australia and New Zealand, we offer investors a gateway to a market projected to witness exponential growth. Our integrated cross-border logistics solutions ensure seamless parcel consolidation, air freight forwarding, and customs clearance, catering to the evolving needs of online businesses.
Strategic Expansion: With plans to establish ground transportation and customs clearance teams, we are poised to capture a significant market share.
Profitable Partnerships: As an IATA-accredited cargo agent with strong ties to top air freight carriers, we guarantee cost-effective solutions.
Robust Growth: Amidst a booming e-commerce market, our stable business model promises lucrative returns for investors seeking long-term opportunities.
Innovative Solutions: Our all-in-one shipping solution ensures operational efficiency and customer satisfaction, positioning us as industry leaders.
Invest in Globavend today and be part of a transformative journey reshaping the future of global logistics.
$CBMJ Targets $5/7/$14..Chart reset for next move up!
PATRIOT.TV Gaining More Viewers Daily.
Watch: https://patriot.tv/
Technical chart PlantX; https://www.barchart.com/stocks/quotes/PLTXF/opinion (OTC/CAN)
See the jump about a month ago - this one is ready for some serious moves IMO.
Canadian stockexchange; https://www.barchart.com/stocks/quotes/VEGA.CN/opinion
bottoms..............................SNAX......GRDI....ZVIA........MULN........https://stockcharts.com/h-sc/ui?s=MULN&p=W&b=5&g=0&id=p84354014936
https://stockcharts.com/h-sc/ui?s=ZVIA&p=W&b=5&g=0&id=p84354014936
https://stockcharts.com/h-sc/ui?s=GRDI&p=W&b=5&g=0&id=p84354014936
https://stockcharts.com/h-sc/ui?s=SNAX&p=W&b=5&g=0&id=p84354014936
VZLA.......LLAP.......MULN..........................https://stockcharts.com/h-sc/ui?s=MULN&p=W&b=5&g=0&id=p84354014936
https://stockcharts.com/h-sc/ui?s=VZLA&p=W&b=5&g=0&id=p84354014936
https://stockcharts.com/h-sc/ui?s=LLAP&p=W&b=5&g=0&id=p84354014936
Followers
|
1891
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
182962
|
Created
|
11/19/12
|
Type
|
Free
|
Moderator $treet $inatra | |||
Assistants Smart Money smart money tracker acsmartmoney Smart Money Stocks __SmartMoney__ |
Posts Today
|
0
|
Posts (Total)
|
182962
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |